Kornimate/medical-research-clean huggingface dataset:
circadian variation of urinary copper excretion in wilson disease patients

Conditions: Wilson Disease

Summary: wilson's disease (wd) is a genetic disorder characterized by an accumulation of copper in the body, mainly in the liver and brain. patients suffering from this disease are monitored by liver function tests, blood copper levels, and 24-hour urinary copper determinations. treatment is based either on chelating the copper accumulated in the body using d-penicillamine or trientine or on limiting intestinal copper absorption with zinc salts. monitoring copper elimination in urine collected over 24 hours is essential for estimating a patient's copper load, adapting treatment dosage, and detecting any copper deficiency. nevertheless, urine collection is often complicated for patients, given the obvious constraints of collecting urine over 24 hours. without this, clinical decisions are usually made based on spot urine. there is no official recommendation for monitoring urinary copper elimination other than on 24-hour urine. according to studies on healthy volunteers under physiological conditions, urinary copper elimination occurs according to a circadian rhythm, with minimal copper elimination between 8 pm and 4 am and maximum between 8 am and noon. the study would aim to find the period of the day best correlated with 24h urinary copper excretion


Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of wilson's disease (leipzig score ˃4). * age ≥ 6 years and ≤70 years. * patient able to perform 24h urine. * current treatment with d-pencillamine, trientine or zinc. * non-opposition of patient and/or legal representatives for minor patients. exclusion criteria: * patients who had a change in treatment within the last 6 months before the inclusion * patients who have undergone liver transplantation * patients with known chronic renal failure (gfr \< 30 ml/min) * patients on long-term diuretic or corticosteroid therapy * persons deprived of liberty by a judicial or administrative decision * patient under judicial protection, unable to express consent

Keywords: wilson disease urinary copper chelator
chemoembolisation of non resectable, non metastatic hepatocellular carcinomas

Conditions: Carcinoma, Hepatocellular

Summary: the purpose of this study is to determine the maximal tolerated dose of idarubicin for chemoembolization of non resectable non metastatic hepatocellular carcinoma.

hepatocellular carcinoma (hcc) is the fifth most common malignancy and the third most common cause of cancer-related death worldwide. most of the patients are diagnosed at intermediate-advanced stage when the sole standard treatment is transarterial chemoembolization (tace). in the literature, survival rates in tace studies vary widely and finally, there is no suggestion for the best chemotherapeutic agent or the optimal treatment regimen. we hypothesise that the use of idarubicin (the most cytotoxic drug on hcc cell lines) in dc bead would enhance the efficacy of tace. the primary objective of the study is to determine the maximal tolerated dose of idarubicin in dc bead for chemoembolization of non resectable non metastatic hepatocellular carcinoma.

Eligibility criteria:
inclusion criteria: * hepatocellular carcinoma cytologically or histologically proved or diagnosed according the criteria of the american association for the study of liver diseases(aasld 2005) * three nodules maximum (unilobar disease without limitation in the number of nodules; 3 maximum nodules if bilobar disease \[satellite nodules \<1cm not included in the total sum\]) * child-pugh score a or b7 * ecog performance status \< 2 * platelet count \> 50,000/µl and absolute neutrophil count (anc) \>1,000/µl * serum creatinine \< 150 µmol/l * resting ejection fraction \> 50% (echocardiography or isotopic method) * age \> 18 years * signed written informed consent exclusion criteria: * patients eligible for surgical resection or hepatic transplantation or radiofrequency ablation * extrahepatic metastases * known gastrointestinal bleeding up to 30 days before study entry * patients with anticoagulant treatment * evidence of portal vein thrombosis * pregnancy * clinically serious infection * known hypersensitivity to anthracyclines * known hypersensitivity to contrast medium
implementation of a fitness education and training program to support safe patient handling and safe lifting

Conditions: Lower Back Injury

Summary: this project involves the delivery of education and training sessions to seven oaks general hospital (sogh) staff, with the goal of workplace injury prevention. education will include review of provincial safe patient handling and back injury prevention guidelines and review of core fitness competencies required to comply with injury prevention standards. training sessions will include exercises to improve core, gluteal and quadricep strength, hip/knee mobility and hamstring flexibility. training will also be an opportunity to provide feedback on functional movement performance. outcomes will include questionnaires on: low back pain/dysfunction; movement confidence; work injury rates and participant satisfaction with program. the project will advise stakeholders of the benefits and challenges associated with implementation of a fitness program to support safe patient handling techniques, as outlined in the provincial guidelines for healthcare workers.

the fit for work project is an educational and training program outcome evaluation. it is a two-part education and practical program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury. in the first part, participants will attend the education session developed by physiotherapists who specialize in return to work programs. in the second part participants will participate in a 4-week practical program, where they will stretch, lengthen and strengthen key muscles used in squatting, weight shifting and the hip hinge movement. feedback and movement coaching are an important element in performing and mastering these movements correctly and this workplace wellness training program will provide staff the support needed.

Eligibility criteria:
inclusion criteria: * male or female, age 18 years or older * staff of seven oaks general hospital during the time of the program * able to communicate in english and provide written informed consent exclusion criteria: * an acute injury, a medical condition, or other personal reason inhibiting participation in all 4 weeks of exercise training sessions

Keywords: safe patient handling safe lifting injury prevention. program outcome evaluation
a study of recombinant vaccinia virus to evaluate the safety and efficacy of a transdermal injection within the tumor of patients with primary or metastatic hepatic carcinoma

Conditions: Neoplasms, Liver

Summary: the primary purpose of this study is to determine the maximum tolerable dose (mtd) and/or the maximum feasible dose (mfd), as well as to evaluate the safety of jx-594 (pexa-vec) injected within hepatic carcinoma tumors.

patients are treated with jx-594 once every three weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments; four additional cycles can be administered to patients with an objective response of the injected tumor(s) (i.e. 8 total treatments possible). study dose levels are 1e8 pfu, 3e8 pfu, 1e9 pfu and 3e9 pfu per treatment. standard phase i dose-escalation guidelines are used, with 2-6 patients enrolled per cohort (3 if no dose-limiting toxicities are reported).

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients with hepatic carcinoma (primary or metastatic) clinically or histologically confirmed to have tumors (≤10cm maximum diameter) that are progressing (refractory to standard treatment) despite regular treatment and that can be transdermally accessed by an injection needle in an imaging-guided procedure * tumor progression despite undergoing regular treatment such as surgery, transarterial chemoembolization, chemotherapy, and radiotherapy * performance score: karnofsky performance score (kps) ≥70 * expected survival of at least 16 weeks * for patients who are sexually active, able and willing to use contraceptives for a three month period during and after taking jx-594 * wbc \> 3,500 cells/mm3 * anc \> 1,500 cells/mm3 * hemoglobin \> 10g/dl * platelet count \> 75,000 plts/mm3 * serum creatinine \< 1.5 mg/dl * ast, alt \< 2.5 x uln * total bilirubin ≤ 2.0 mg/dl * in patients with primary hcc, child pugh a or b * able/willing to sign an irb/iec/reb-approved written consent form * able and willing to comply with study procedures and follow-up examinations exclusion criteria: * pregnant or nursing an infant * known infection with hiv * clinically significant active infection or uncontrolled medical condition considered high risk for investigational new drug treatment * significant immunodeficiency due to underlying illness (e.g. hematological malignancies, congenital immunodeficiencies and/or hiv infection/aids) and/or medication (e.g. high-dose systemic corticosteroids) * patients with household contacts with significant immunodeficiency * history of exfoliative skin condition (e.g. severe eczema, ectopic dermatitis, or similar skin disorder) that at some stage has required systemic therapy * severe or unstable cardiac disease * use of adrenal cortical hormone drug or immunosuppressant within four weeks of study enrollment

Keywords: jennerex unresectable liver tumors primary liver cancer metastatic liver cancer oncolytic virus vaccinia virus pexa-vec
the safety of pharmacopuncture on musculoskeletal patients

Conditions: Musculoskeletal Diseases or Conditions; Spine; Arthrosis

Summary: the purpose of this study is to evaluate the safety of pharmacopuncture by observing any adverse events that may occur after pharmacopuncture treatment in with spinal joint disease hospitalized patients at 7 korean medicine hospitals and analyzing blood test results.

this study was an registry observational study, and was conducted in 7 korean medicine hospitals (160 patients at jaseng korean medicine hospital, 140 patients at daejeon jaseng hospital of korean medicine, 140 patients at bucheon jaseng hospital of korean medicine, 140 patients at haeundae jaseng korean medicine hospital, 140 patients at kyunghee university of korean medicine hospital, 140 patients at kyung hee university of korean medicine hospital at gangdong, and 140 patients at dongguk university bundang oriental hospital).

Eligibility criteria:
inclusion criteria: * inpatients with diagnosed spinal joint disease * patients who received pharmacopuncture treatment during hospitalization * patients who are 19 years of age or older and less than 70 years old * patients who agreed to participate in the clinical study and voluntarily given written informed consent exclusion criteria: * patients with difficulty or refusal to give sign written informed consent * patients for whom the researchers judge participation in the clinical study to be difficult

Keywords: spinal joint safety pharmacopuncture adverse event
children with fever and respiratory symptoms at out-of-hours services in norway

Conditions: Children

Summary: viral self-limiting infections in respiratory organs among children are common in primary care. serious infections have low prevalence and are challenging to distinguish from self-limiting infections. prescription of antibiotics in primary care is still high but stable since 2009 in norway, and 90% of all antibiotics are prescribed in primary care. c-reactive protein (crp) has been especially popular in norway for point-of-care testing in primary care, but its role in ruling-out serious infections and the cut-off value for prescribing antibiotics has been discussed a lot. the aim of this study is to identify if pretesting with crp of all children 0-6 year with fever or respiratory symptoms at out-of-hours services will affect the prescription of antibiotics and the referral to hospital for children.

design: a randomized controlled observational study including children 0-6 year with fever and/or respiratory symptoms at 4 different out-of-hour services and at 1 emergency children department clinic at a hospital (open clinic). the data consist of clinical data and anamnestic information from a nurse at ooh-service collected before the consultation, the doctor's journal and a questionnaire to parents before the consultation and 1 week after the consultation.

Eligibility criteria:
inclusion criteria: * children 0-6 years with fever and/or respiratory symptoms exclusion criteria: * children older than 6 years with other conditions

Keywords: c-reactive protein primary health care child welfare after-hours care anti-bacterial agents drug prescriptions
supar is a potential biomarker of in chronic periodontitis through the impact of post-radiotherapy on hncs patients

Conditions: Head and Neck Cancer; Chronic Periodontitis; Radiotherapy; Complications

Summary: this study aims to improve a soluble urokinase plasminogen activator receptor supar is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (hnc post-rt).

the urokinase-type plasminogen activator receptor (upar) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of chronic periodontitis. the study enrolled 150 participants, 50 chronic periodontitis with head and neck cancer post radiotherapy (cp+hnc post-rt) patients, 50 chronic periodontitis (cp) without hnc patients, and 50 healthy controls. clinical attachment loss (cal), probing pocket depth (ppd), plaque index (pi), and gingival bleeding index (gbi) were recorded. an enzyme-linked immunosorbent assay (elisa) was constructed to quantify serum (supar) levels. stage and grade of periodontitis were stage iii-iv, grade c in patients (cp+hnc post-rt), stage i-iii, grade a/b in patients (cp without hnc), and absent in (healthy). chronic periodontitis with hnc post-rt patients presented a significantly higher proportion of supar levels (506.7 pg/ml) compared to chronic periodontitis without hnc and healthy controls (423.08 pg/ml and 255.9 pg/ml), respectively. a significant positive correlation was found between serum supar levels and cal, ppd, pi, and gbi in the periodontal disease groups. roc results of supar (auc=0.976 for cp+hnc post-rt, auc=0.872 for cp without hnc). hyposalivation appeared in patients (cp+hnc post-rt; 0.15 \[0.11-0.23\] ml/min, p=0.001) and (cp without hnc; 0.30 \[0.25-0.41\] ml/min, p=0.001), compared to healthy controls; 0.35 \[0.28- 0.54\] ml/min, p=0.001). the study showed a significant elevation in serum supar levels in cp+hnc post-rt patients compared to the cp without hnc and control groups.

Eligibility criteria:
inclusion criteria: * a pathologically confirmed malignant neoplasm of hnc (derived from epithelial cells). * not having received radiation therapy previously. * no distant metastasis. * no history of salivary gland surgery (parotid, submandibular, or sublingual). * a generally satisfactory physical condition with a performance score of 0 to 1 point and a planned survival period of more than a year and scores of 2 higher indicating increasing disability. exclusion criteria: * previous oral disease or salivary gland disease history. * definitive diagnosis of multiple sclerosis, xerostomia, or systemic disease. * refusal to participate in the study.
trial of vacuum assisted closure® therapy versus control therapy in angiogenesis

Conditions: Wounds

Summary: the purpose of this study is to determine: 1. if vacuum assisted closure (vac®) therapy results in altered proteomic expression of angiogenic markers compared to moist wound therapy. 2. if vac® therapy results in increased angiogenesis compared to moist wound therapy.


Eligibility criteria:
inclusion criteria: * patient is male or female and \> 18 years old. * patient or patient's legal authorized representative is willing to sign informed consent. * patient has a post surgical dehisced wound of the lower extremity for longer than two weeks and less than one month. * patient has transcutaneous oximetry (tcpo2) evaluation that demonstrated tissue hypoxia in the periwound region, as indicated by a reading of 10-40 mmhg within the prior two weeks. * ankle brachial index \> 0.7 within the prior two weeks. * patient is not pregnant (pregnancy test is negative) and non-lactating at visit 1. * patient does not plan on becoming pregnant during the course of the study. * patient is willing to use effective method of contraception for the duration of the study, is permanently sterilized, or post-menopausal as defined by cessation of menses for at least one year prior to enrollment in study. exclusion criteria: * diagnosed and untreated wound infection. * poor nutrition status as evidenced by pre-albumin \< 12mg/dl within the past 30 days or extracellular mass \< 95%. * presence of sickle cell disease. * presence of connective tissue disease (e.g. history of or active lupus). * hemoglobin a1c (hba1c) levels greater than 9% thirty days prior to screening visit (if patient is confirmed diabetic). * treatment with an investigational therapy within the previous 30 days. * lower extremity wound (under consideration for study) with malignancy. * lower extremity wound (under consideration for study) with untreatable cellulitis. * presence of untreated osteomyelitis. * presence of any systemic hematologic disorder or condition that would impede healing. * history of radiation to the wound area. * history of drugs that may delay wound healing. * history of thermal injury to the wound area. * prior vac® therapy to the wound within 30 days of enrollment. * current or prior treatment with hyperbaric oxygen therapy (hbo) or warm-up therapy to the same wound. * recent diagnosis of cancer or active management of cancer within the last year. * treatment with skin or dermal substitutes or dressings with living cells capable of producing growth factors within the previous 30 days. * end stage renal disease. * history of alcohol or drug abuse that may impact protocol compliance or delay wound healing. * known hypersensitivity to hydrogel or any disposable component of the vac® therapy system. * necrotic tissue with eschar present which cannot be debrided. * any other severe concurrent disease, which, in the judgment of the investigator, would make the patient inappropriate for entry into the study.

Keywords: angiogenesis post surgical dehisced wounds of the lower extremity
the role of n-acetylcysteine as a novel adjuvant treatment in acute organophosphorus pesticide poisoning

Conditions: Acute Organophosphorus Poisoned Patients

Summary: all patients admitted in the icu of the pcc-asuh due to acute poisoning by acute organophosphorus poisoning will be included in the study. the diagnosis of intoxication will be based on history of acute exposure , clinical examination and laboratory investigations. patients will be randomly allocated into 2 equal groups. group 1 -. patients who will receive (conventional treatment of acute organophosphorus poisoning plus nac) and group 2 - patients who will receive conventional treatment only

40 patients with acute organophosphorus poisoning will be randomly assigned as control groups and study group in a 1:1 ratio ( 20 patients in each group). the diagnosis of acute organophosphorus intoxication will be based on history of acute exposure, clinical examination and laboratory investigations. patients will be randomly allocated into 2 equal groups. group 1 - patients who will receive (conventional treatment of acute organophosphorus poisoning plus nac) group 2 - patients who will receive conventional treatment only

Eligibility criteria:
inclusion criteria: all patients (above 16 years) admitted to the icu of the pcc-asuh due to acute poisoning by acute organophosphorus poisoning will be included in the study. the diagnosis of intoxication will be based on history of acute exposure, clinical examination and laboratory investigations. - exclusion criteria: * based on the possibility of alteration in measured parameters and/or biomarkers, patients below 16 years or above 60 years patients with history of diabetes, cardiac disease, respiratory, renal disease and hepatic disease.
prevention of pneumonia comparing ceftriaxone with subglottic aspiration

Conditions: Pneumonia

Summary: the primary purpose of the trial is to compare the efficacy and safety of two measures which claim to prevent early-onset ventilator-associated pneumonia.

background: in a previous double-blind, placebo-controlled, randomized trial we found that a 3-day-course of ceftriaxone significantly reduced the incidence of early-onset ventilator-associated pneumonia (eop). continuous aspiration of secretions accumulating in the subglottic space above the cuff of the endotracheal tube has also been shown to prevent eop. objective: to compare the effect of both preventive measures on the incidence of eop. design: randomized, multicenter. setting: three general intensive care units at university hospitals in spain. patients: patients without signs of infection and no concomitant systemic antibiotics were included if expected to require endotracheal intubation exceeding 2 days. intervention: all patients were intubated with an endotracheal tube equipped with a port for aspiration of subglottic secretions and subsequently randomized to receive a three day course of 2 gram/day iv ceftriaxone without aspiration of subglottic secretions or continuous aspiration of subglottic secretions. measurements: all icu-acquired infections, antibiotic therapy, colonization and infection with 3rd-generation cephalosporin-resistant microorganisms, duration of intubation and icu-stay and-mortality.

Eligibility criteria:
inclusion criteria: * endotracheal intubation with endotracheal tube equipped with port for aspirations of subglottic contents and expected to exceed 48 hors. * absence of infection. * 18 years or older. * informed consent. exclusion criteria: * endotracheal intubation prior to admission to hospital. * allergic to beta-lactam antibiotics. * formal indication for systemic antibiotic therapy.

Keywords: prevention of pneumonia ceftriaxone continuous aspiration subglottic secretions mechanical ventilation with endotracheal intubation. absence of infection
clinical performance evaluation of dxn hbv assay

Conditions: Hepatitis B

Summary: the dxn hepatitis b virus (hbv) assay is an in vitro diagnostic assay intended as an aid in the management of hbv-infected individuals undergoing antiviral therapy. the purpose of the study is to establish the clinical performance of the dxn hbv assay for plasma samples in the intended use population.

same as brief summary.

Eligibility criteria:
inclusion criteria: * subject is 18 years of age or older * subject has serological evidence of chronic hbv infection, and measurable hbv-dna and alt at baseline * subject will undergo treatment with tenofovir or entecavir for a minimum of 48 weeks exclusion criteria: * co-infection with hiv or hcv at enrollment * subject has decompensated liver disease or liver cancer * prior participation in study * current or planned participation in an investigational drug or device study
biochemical marker to predict the recurrence of atrial fibrillation after surgical maze procedure

Conditions: Atrial Fibrillation

Summary: the role of plasma nt-probnp, hscrp, timp-1(tissue inhibitors of metalloproteinase-1),tgf-b, mmp-3(matrix metalloproteinase-3), and pro-mmp-1 in predicting the recurrence of af after surgical maze procedure. the association of expression of ctgf, tgf-b, bnp, anp, collagen-1, and collagen-3 in la with the recurrence of af after surgical maze procedure.


Eligibility criteria:
inclusion criteria: * the patients who have valvular heart disease with atrial fibrillation and are scheduled for operation exclusion criteria: * coronary heart disease * congestive heart failure

Keywords: atrial fibrillation maze procedure